Figure 4

Disease progression in commercially derived transgenic progeny. Kaplan-Meier analysis did not indicate a significant difference between sexes for disease onset (p = 0.0926), although presentation of disease symptoms was slightly later in males. Males exhibited an increased lifespan compared to females (p < 0.0001). Commercial Male n = 12; mean age of onset/lifespan: 357/624d; Commercial Female n = 9 mean age of onset/lifespan: 304/563d).